Abstract
Fingolimod, a sphingosine-1-phosphate receptor modulator, was the first oral disease-modifying drug approved for relapsing-remitting multiple sclerosis (RRMS).1 Fingolimod decreases multiple sclerosis disease activity through a presumed mechanism of sequestration of lymphocytes in lymph nodes, thereby reducing circulating lymphocytes available for entry into the CNS. Its lymphopenic effect has raised concern for predisposition to opportunistic infections.2 Recently, the US Food and Drug Administration (FDA) issued a new warning on labeling for fingolimod following reports of 2 cases of progressive multifocal leukoencephalopathy (PML) associated with fingolimod therapy.3
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
